IN2012DN02763A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02763A IN2012DN02763A IN2763DEN2012A IN2012DN02763A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A IN 2763DEN2012 A IN2763DEN2012 A IN 2763DEN2012A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A
- Authority
- IN
- India
- Prior art keywords
- disease
- kinase activity
- lrrk2 kinase
- larly
- particu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24655009P | 2009-09-29 | 2009-09-29 | |
| CN2010001334 | 2010-09-02 | ||
| PCT/CN2010/001501 WO2011038572A1 (en) | 2009-09-29 | 2010-09-27 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02763A true IN2012DN02763A (es) | 2015-09-18 |
Family
ID=43825509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2763DEN2012 IN2012DN02763A (es) | 2009-09-29 | 2010-09-27 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8778939B2 (es) |
| EP (1) | EP2483254B1 (es) |
| JP (1) | JP5752691B2 (es) |
| KR (1) | KR20120081609A (es) |
| AU (1) | AU2010302842B2 (es) |
| BR (1) | BR112012006859A2 (es) |
| CA (1) | CA2775753A1 (es) |
| EA (1) | EA021437B1 (es) |
| ES (1) | ES2512727T3 (es) |
| IL (1) | IL218674A (es) |
| IN (1) | IN2012DN02763A (es) |
| MX (1) | MX2012003778A (es) |
| SG (1) | SG179120A1 (es) |
| WO (1) | WO2011038572A1 (es) |
| ZA (1) | ZA201201877B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2576541T3 (pl) | 2010-06-04 | 2016-10-31 | Pochodne aminopirymidyny jako modulatory lrrk2 | |
| WO2012028629A1 (en) * | 2010-09-02 | 2012-03-08 | Glaxo Group Limited | 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors |
| LT3124483T (lt) | 2010-11-10 | 2019-09-25 | Genentech, Inc. | Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai |
| CA2834928C (en) | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2012162254A1 (en) | 2011-05-23 | 2012-11-29 | Elan Pharmaceuticals, Inc. | Inhibitors of lrrk2 kinase activity |
| WO2013046029A1 (en) * | 2011-09-30 | 2013-04-04 | Ipsen Pharma S.A.S. | Macrocyclic lrrk2 kinase inhibitors |
| MX349556B (es) | 2011-11-29 | 2017-08-03 | Genentech Inc | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). |
| SI2785711T1 (sl) | 2011-11-29 | 2016-12-30 | F. Hoffmann-La Roche Ag | 2-(fenil ali pirid-3-il)aminopirimidinski derivati kot modulatorji kinaze LRRK2 za zdravljenje Parkinsonove bolezni |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| BR112014011219B1 (pt) | 2011-11-29 | 2022-08-23 | Genentech, Inc. | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| JP6148248B2 (ja) * | 2011-11-30 | 2017-06-14 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２のポジトロン放出断層撮影（ｐｅｔ）イメージングのためのフッ素−１８及び炭素−１１標識放射性リガンド |
| MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
| ES2865058T3 (es) * | 2013-12-09 | 2021-10-14 | Unichem Lab Ltd | Un proceso mejorado para la preparación de (3R,4R)-(1-bencil-4-metilpiperidin-3-il)-metilamina |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| EP3099694B1 (en) | 2014-01-29 | 2019-01-16 | GlaxoSmithKline Intellectual Property Development Limited | Compounds |
| UA118369C2 (uk) * | 2014-01-29 | 2019-01-10 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Сполуки, що інгібують активність lrrk2 кінази |
| JP2017511340A (ja) * | 2014-03-31 | 2017-04-20 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | ヒストンアセチルトランスフェラーゼ活性剤及びその使用 |
| WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
| WO2016016369A1 (en) | 2014-07-31 | 2016-02-04 | Basf Se | Process for preparing pyrazoles |
| CN105348182B (zh) * | 2014-08-24 | 2018-04-13 | 复旦大学 | 2‑烷氧基苯甲酰芳胺类化合物及其药物用途 |
| CA2960777A1 (en) | 2014-09-17 | 2016-03-24 | Oncodesign S.A. | Macrocyclic lrrk2 kinase inhibitors |
| JP6612874B2 (ja) | 2014-12-16 | 2019-11-27 | アクソファント サイエンシーズ ゲーエムベーハー | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 |
| US10584102B2 (en) * | 2015-05-11 | 2020-03-10 | Basf Se | Process for preparing 4-amino-pyridazines |
| DK3294725T3 (da) * | 2015-05-11 | 2021-07-26 | Basf Se | Fremgangsmåde til fremstilling af 4-aminopyridaziner |
| RU2017145964A (ru) | 2015-06-10 | 2019-07-10 | Аксовант Сайенсиз Гмбх | Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов |
| JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
| WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
| BR112019000569A2 (pt) | 2016-07-12 | 2019-04-24 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como pesticidas |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| EP3573956A4 (en) * | 2017-01-25 | 2020-08-12 | GlaxoSmithKline Intellectual Property Management Limited | LINKS |
| CN110678182B (zh) * | 2017-02-24 | 2022-08-23 | 大邱庆北尖端医疗产业振兴财团 | 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物 |
| KR101990739B1 (ko) | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101990738B1 (ko) | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101992059B1 (ko) | 2018-08-23 | 2019-06-21 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| US20220396575A1 (en) | 2019-08-30 | 2022-12-15 | Tsd Life Sciences Co., Ltd. | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449691A (en) * | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
| EP0848700B1 (de) * | 1995-08-30 | 2003-07-02 | Bayer CropScience AG | Acylaminosalicylsäureamide und ihre verwendung als schädlingsbekämpfungsmittel |
| PH11998001072B1 (en) | 1997-05-07 | 2006-11-21 | Univ Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU8270898A (en) | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
| NZ507760A (en) | 1998-03-26 | 2002-10-25 | Japan Tobacco Inc | Amide derivatives and nociceptin antagonists |
| WO2001070734A2 (en) | 2000-03-17 | 2001-09-27 | Bristol-Myers Squibb Pharma Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| DE10159453A1 (de) | 2001-12-04 | 2003-06-18 | Merck Patent Gmbh | Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease |
| EP1497260A1 (en) | 2002-04-09 | 2005-01-19 | 7TM Pharma A/S | Novel methoxybenzamide compounds for use in mch receptor related disorders |
| WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
| AU2004236248A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Phenyl substituted carboxylic acids |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| US20090239860A1 (en) * | 2004-01-28 | 2009-09-24 | Tetsuya Nakamura | Novel benzofuran derivative, medicinal composition containing the same, and uses of these |
| TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
| US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
| US20060276496A1 (en) * | 2005-03-17 | 2006-12-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-Cytokine Heterocyclic Compounds |
| AU2006287521A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
| JP2007176799A (ja) | 2005-12-27 | 2007-07-12 | Sankyo Co Ltd | 置換ベンゼン化合物を含有する医薬 |
| MX2008011136A (es) * | 2006-03-07 | 2008-09-08 | Squibb Bristol Myers Co | Compuestos de profamarco de pirrolotriazina anilina utiles como inhibidores de cinasa. |
| JP2009535318A (ja) | 2006-04-28 | 2009-10-01 | トランステック ファーマ，インコーポレイティド | ベンズアミドグルコキナーゼ活性化剤 |
| KR20090089868A (ko) * | 2006-12-15 | 2009-08-24 | 글락소 그룹 리미티드 | Ｅｐ４ 수용체 작동제로서 벤즈아미드 유도체 |
| WO2009030270A1 (en) | 2007-09-03 | 2009-03-12 | Novartis Ag | Dihydroindole derivatives useful in parkinson's disease |
| GB0722680D0 (en) | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
| US20110230536A1 (en) | 2008-10-24 | 2011-09-22 | Calcimedica, Inc. | Phenylpyrazole inhibitors of store operated calcium release |
-
2010
- 2010-09-27 ES ES10819801.1T patent/ES2512727T3/es active Active
- 2010-09-27 KR KR1020127010852A patent/KR20120081609A/ko active IP Right Grant
- 2010-09-27 WO PCT/CN2010/001501 patent/WO2011038572A1/en active Application Filing
- 2010-09-27 SG SG2012017760A patent/SG179120A1/en unknown
- 2010-09-27 JP JP2012531212A patent/JP5752691B2/ja not_active Expired - Fee Related
- 2010-09-27 BR BR112012006859A patent/BR112012006859A2/pt not_active IP Right Cessation
- 2010-09-27 US US13/498,975 patent/US8778939B2/en not_active Expired - Fee Related
- 2010-09-27 IN IN2763DEN2012 patent/IN2012DN02763A/en unknown
- 2010-09-27 EP EP10819801.1A patent/EP2483254B1/en active Active
- 2010-09-27 CA CA2775753A patent/CA2775753A1/en not_active Abandoned
- 2010-09-27 MX MX2012003778A patent/MX2012003778A/es active IP Right Grant
- 2010-09-27 EA EA201270480A patent/EA021437B1/ru not_active IP Right Cessation
- 2010-09-27 AU AU2010302842A patent/AU2010302842B2/en not_active Ceased
-
2012
- 2012-03-14 ZA ZA2012/01877A patent/ZA201201877B/en unknown
- 2012-03-15 IL IL218674A patent/IL218674A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP5752691B2 (ja) | 2015-07-22 |
| AU2010302842B2 (en) | 2014-05-08 |
| EP2483254B1 (en) | 2014-08-13 |
| AU2010302842A1 (en) | 2012-04-12 |
| EP2483254A1 (en) | 2012-08-08 |
| US20120184553A1 (en) | 2012-07-19 |
| WO2011038572A1 (en) | 2011-04-07 |
| BR112012006859A2 (pt) | 2019-09-24 |
| MX2012003778A (es) | 2012-06-01 |
| JP2013505969A (ja) | 2013-02-21 |
| EA201270480A1 (ru) | 2013-08-30 |
| KR20120081609A (ko) | 2012-07-19 |
| EA021437B1 (ru) | 2015-06-30 |
| ES2512727T3 (es) | 2014-10-24 |
| IL218674A (en) | 2015-11-30 |
| ZA201201877B (en) | 2012-11-28 |
| EP2483254A4 (en) | 2013-02-27 |
| US8778939B2 (en) | 2014-07-15 |
| CA2775753A1 (en) | 2011-04-07 |
| SG179120A1 (en) | 2012-05-30 |
| IL218674A0 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02763A (es) | ||
| TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| MX2009000333A (es) | Pirrilopirimidinas para composiciones farmaceuticas. | |
| TW200800968A (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
| BR112012006858A2 (pt) | metodo de aperfeicoamento do desempenho de impressao em placas de impressao flexografica | |
| MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
| MX2011011661A (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. | |
| UA94944C2 (ru) | 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла | |
| MX342177B (es) | Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. | |
| MX2007008790A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso. | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| TNSN07383A1 (en) | 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands | |
| MX2012004548A (es) | Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central. | |
| AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
| TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases | |
| TW200726763A (en) | Novel compound | |
| MX2010009837A (es) | Tiazolil-dihidro-indazoles. | |
| WO2010129665A3 (en) | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | |
| TN2011000531A1 (en) | 5- alkynyl - pyridines | |
| WO2011008675A3 (en) | Catecholamine compounds, compositions, and formulations, and methods of using the same | |
| WO2009151495A3 (en) | Oxazole compounds, compositions and methods of use | |
| MX2012008359A (es) | 5-alquinil pirimidinas y su uso como inhibidores de quinasa. |